H World Group Posts Upbeat Q3 Earnings, Joins CG Oncology, TELUS And Other Big Stocks Moving Higher On Monday
U.S. stocks fell, but H World Group surged 9.3% on strong Q3 results and raised guidance; several other stocks posted notable gains.
Stocks · News reference
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Fennec Pharmaceuticals (NASDAQ:FENC) with a Buy and maintains $16 price target.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
U.S. stocks fell, but H World Group surged 9.3% on strong Q3 results and raised guidance; several other stocks posted notable gains.
B. Riley has increased its price target for Fennec Pharmaceuticals from $18 to $19 while maintaining a "Buy" rating.
Fennec Pharmaceuticals announced its financial results for the third quarter ended September 30, 2026, reporting net product sales of $19.4 million and a cash position of $48.7 million.
Fennec Pharmaceuticals Inc. announced it will release its third quarter 2026 financial results before the U.S. market opens on November 12, 2026.
Fennec Pharmaceuticals Inc. is set to release its financial results for the third quarter of 2026 on November 5, 2026.
Filed: 2026-09-17 AccNo: 0001104659-26-108565 Size: 220 KB Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits